skip to primary navigationskip to content
 

Charlotte Coles

Dr Charlotte ColesCharlotte Coles



Websites


Graduate Students

 Dr Charlotte Coles is pleased to consider applications from prospective PhD students.


Research Interests

I lead a national portfolio of breast cancer RT studies and translational research which aims to provide breast cancer patients with the best chance of cure with least side effects:

  • IMPORT LOW (n=2018): intensity modulated radiotherapy (IMRT) and partial breast radiotherapy (PBRT) in patients at low risk of recurrence – in follow up
  • IMPORT HIGH (n=2621): dose-escalated IMRT for patients at higher risk of recurrence - in follow up
  • PRIMETIME (n=2200): Post-operative avoidance of RT in minimal risk women: patient selection using biomarkers – in set up
  • NEO-RT (n=50): pre-operative breast IMRT in patients receiving neo-adjuvant hormonal treatment – in set up

Potential benefit for Patients:

  • Safe reduction of whole breast plus boost RT for high risk patients from 4.5 weeks to 3 weeks
  • Minimising side effects whilst maintaining local control with PBRT for low risk patients
  • Safe avoidance of RT for patients at very low risk of recurrence
  • Possible avoidance of mastectomy following neo-adjuvant RT and endocrine therapy
  • Development of molecular profiles to predict recurrence risk and normal tissue toxicity following RT
  • Potential Benefits for NHS:

Potential Benefits for NHS:

  •  Implementation of high quality IMRT and PBRT as standard of care
  • Use of a cost-effective predictive marker for safe RT avoidance
  • Reduction in number of fractions and RT avoidance saving the NHS >£12million/year

I am also editor of Clinical Oncology journal: www.clinicaloncologyonline.net/


Publications

Pubmed journal articles - pubmed

Key publications

Mukesh MB, Qian W, Wilkinson JS, Dorling L, Barnett GC, Moody AM, Wilson C, Twyman N, Burnet NG, Wishart GC, Coles CE. Patient reported outcome measures (PROMs) following forward planned field-in field IMRT: results from the Cambridge Breast IMRT trial. Radiother Oncol. 2014 May;111(2):270-5.


Barnett GC, Thompson D, Fachal L, Kerns S, Talbot C, Elliott RM, Dorling L, Coles CE, et al. A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity. Radiother Oncol. 2014 May;111(2):178-85.


Mukesh MB, Barnett GC, Wilkinson JS, Moody AM, Wilson CB, Dorling L, Chan Wah Hak C, Qian W, Twyman N, Burnet NG, Wishart GC and Coles CE. A randomised controlled trial of Intensity Modulated Radiotherapy (IMRT) for early breast cancer: 5-year results confirm superior overall cosmesis. Journal of Clinical Oncology 2013. 31; 36: 4488-95


Mukesh MB, Harris E, Collette S, Coles CE, Bartelink H, Wilkinson J, Evans PM, Graham P, Haviland J, Poortmans P, Yarnold J, Jena R. Normal tissue complication probability (NTCP) parameters for breast fibrosis: Pooled results from two randomised trials. Radiother Oncol. 2013. 108; 2: 293-8


Kirby AN, Jena R, Harris EJ, Evans PM, Crowley C, Gregory DL, Coles CE. Tumour bed delineation for partial breast/breast boost radiotherapy: What is the optimal number of implanted markers? Radiother Oncol. 2013. 106; 2: 231-5


Barnett GC, Coles CE, et al. Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. Lancet Oncology 2012. 13; 1: 65-77


Barnett GC, Wilkinson JS, Moody AM, Wilson CB, Twyman N, Wishart GC, Burnet NG, Coles CE. A randomised controlled trial of forward-planned Intensity Modulated Radiotherapy (IMRT) for early breast cancer: interim results at 2 years. Int J Radiat Oncol Biol Phys 2012. 82; 2: 715-23

GC Barnett, JS Wilkinson, AM Moody, CB Wilson, N Twyman, GC Wishart, NG Burnet, CE Coles. The Cambridge Breast IMRT trial: patient and treatment-related factors which influence late toxicity. Clinical Oncology 2011.10: 662-73

Coles CE, Harris EJ, et al. Evaluation of implanted gold seeds for breast radiotherapy planning and on treatment verification: a feasibility study on behalf of the IMPORT trialists. Radiother Oncol 2011. 100; 276–281

Donovan EM, Cuirlionis L, Fairfoul J, James H, Mayles H, Raj S, Tsang Y, Tywman N, Yarnold J, Coles CE. Planning With Intensity-Modulated Radiotherapy and Tomotherapy to Modulate Dose Across Breast to Reflect Recurrence Risk (IMPORT High Trial). Int J Radiat Oncol Biol Phys 2011. 79; 4: 1064-1072